Alongside reducing clinical symptoms of arthritis and synovitis, as already described for CCR2/CCL2 blockade (20), SMI alone or in combination with MTX showed a decrease in bone loss, and the reduction of myeloid lineage cell accumulation locally and in spleen. The gene discussed is CCR2; the disease is arthritic joint disease.